Sartorius Stedim Biotech (DIM) News Today €167.60 +2.05 (+1.24%) As of 08/7/2025 Add Compare Share Share Headlines Stock AnalysisChartHeadlinesBuy This Stock DIM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period 3 European Stocks Estimated At Up To 41.3% Discount To Intrinsic ValueJuly 30, 2025 | finance.yahoo.comEuropean shares end lower as corporate results, trade anxiety weighJuly 23, 2025 | msn.comSartorius Stedim Biotech S.A. (0RG8) Stock Price Today - WSJJuly 16, 2025 | wsj.comSartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible’s Unique Cell-Based mRNA Design and Manufacturing PlatformJuly 9, 2025 | finance.yahoo.comSRTOY - Sartorius Stedim Biotech SA ADR Valuation - MorningstarJune 28, 2025 | morningstar.comMSDMHF - Sartorius Stedim Biotech SA Executives - MorningstarJune 24, 2025 | morningstar.comMSartorius Stedim Biotech And 2 Other Undiscovered Gems With Strong FundamentalsJune 20, 2025 | finance.yahoo.comRBC cuts Sartorius Stedim stock rating, lowers price targetMay 22, 2025 | investing.comSartorius Stedim Biotech publishes unaudited first quarter results for 2025April 16, 2025 | markets.businessinsider.comSartorius Stedim Biotech S.A. - Barron'sApril 7, 2025 | barrons.comResolutions of the Combined Annual Shareholders Meeting of Sartorius Stedim Biotech S.A.March 25, 2025 | finance.yahoo.comSartorius AG and its biotech subsidiary lifted to Buy at BarclaysFebruary 26, 2025 | investing.comRBC Capital Sticks to Its Buy Rating for Sartorius Stedim Biotech (0RG8)February 21, 2025 | markets.businessinsider.comSartorius Stedim Biotech releases Universal Registration Document 2024February 17, 2025 | markets.businessinsider.comSartorius Stedim Biotech Preliminary FY24 Profit Declines - Quick FactsJanuary 28, 2025 | markets.businessinsider.comSartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2024January 28, 2025 | markets.businessinsider.comBernstein Sticks to Their Hold Rating for Sartorius Stedim Biotech (0RG8)January 16, 2025 | markets.businessinsider.comSartorius Stock: JPMorgan Boost Drives 4% Market SurgeJanuary 7, 2025 | finanznachrichten.deRBC Capital Sticks to Its Hold Rating for Sartorius (0NIR)December 9, 2024 | markets.businessinsider.comJefferies Keeps Their Hold Rating on Sartorius (0NIR)November 20, 2024 | markets.businessinsider.comFrance shares lower at close of trade; CAC 40 down 2.69%November 14, 2024 | msn.comFrance stocks lower at close of trade; CAC 40 down 2.69%November 14, 2024 | msn.comFrance shares higher at close of trade; CAC 40 up 0.80%November 2, 2024 | msn.comJefferies Sticks to Their Hold Rating for Sartorius (0NIR)October 28, 2024 | markets.businessinsider.comKepler Capital Remains a Sell on Sartorius (0NIR)October 19, 2024 | markets.businessinsider.comSartorius AG (SARTF) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic GrowthOctober 18, 2024 | finance.yahoo.comRBC Capital Keeps Their Buy Rating on Sartorius Stedim Biotech (0RG8)October 18, 2024 | markets.businessinsider.comSartorius Stedim Biotech SA (SDMHF) Q3 2024 Earnings Call Highlights: Navigating Market ...October 18, 2024 | finance.yahoo.comFrance shares higher at close of trade; CAC 40 up 1.22%October 17, 2024 | msn.comFrance stocks higher at close of trade; CAC 40 up 1.22%October 17, 2024 | msn.comMatica Bio and CytoImmune Establish a Strategic Partnership for Cell Therapy Development and ManufacturingOctober 10, 2024 | businesswire.comSenior Life Sciences Executives Launch Enovo Life Sciences, in Partnership with Warburg PincusOctober 7, 2024 | tmcnet.comJ.P. Morgan Reaffirms Their Buy Rating on Sartorius (0NIR)September 27, 2024 | markets.businessinsider.comSDMHF Sartorius Stedim Biotech S.A.September 21, 2024 | seekingalpha.comSartorius Stedim Biotech S.A. (56S1.DE)September 16, 2024 | sg.finance.yahoo.comFrance shares mixed at close of trade; CAC 40 up 0.99%September 9, 2024 | msn.comFrance shares lower at close of trade; CAC 40 down 1.07%September 7, 2024 | msn.comKepler Capital Sticks to Its Sell Rating for Sartorius (0NIR)September 6, 2024 | markets.businessinsider.comKepler Capital Sticks to Their Hold Rating for Sartorius Stedim Biotech (0RG8)September 6, 2024 | markets.businessinsider.comRBC Capital downgrades Sartorius (0NIR) to a HoldSeptember 2, 2024 | markets.businessinsider.comFrance shares mixed at close of trade; CAC 40 down 0.32%August 27, 2024 | msn.comSartorius Stedim Biotech S.A. (DIMP.XC)August 16, 2024 | finance.yahoo.comBlackRock Greater Europe Investment Trust: High-Quality Fund in Underappreciated RegionAugust 14, 2024 | uk.investing.comViroCell Biologics Completes Oversubscribed FinancingAugust 14, 2024 | finance.yahoo.comSartorius Stedim Biotech S.A. (SRTOY)August 13, 2024 | finance.yahoo.comSRTOY Sartorius Stedim Biotech S.A.August 1, 2024 | seekingalpha.comSartorius (0NIR) Receives a Buy from J.P. MorganJuly 29, 2024 | markets.businessinsider.comSartorius Stedim Biotech S.A. (DIM.VI)July 26, 2024 | uk.finance.yahoo.comSartorius Stedim Biotech S.A. (SDMHF) H1 2024 Earnings Call TranscriptJuly 20, 2024 | seekingalpha.comSartorius Stedim Biotech SA: Half-year results 2024 of SartoriusStedimBiotech -2-July 19, 2024 | finanznachrichten.de Get Sartorius Stedim Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for DIM and its competitors with MarketBeat's FREE daily newsletter. Email Address DIM Media Mentions By Week DIM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DIM News Sentiment▼0.000.38▲Average Medical News Sentiment DIM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DIM Articles This Week▼00▲DIM Articles Average Week Get Sartorius Stedim Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for DIM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Fielmann Group News Sartorius Aktiengesellschaft News Carl Zeiss Meditec News Gerresheimer News Fresenius SE & Co. KGaA News Genfit News Sanofi News Siemens Healthineers News Merck KGaA News Bayer Aktiengesellschaft News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (EPA:DIM) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sartorius Stedim Biotech S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sartorius Stedim Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
